Health Canada
Santé Canada

STATUS DECISION OF CONTROLLED AND NON-CONTROLLED SUBSTANCE(S)

Substance: I- 17b-Hydroxy-5-androstano[3,2-c]pyrazole
II- 5a-N-Acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate
III- 5a-N-Acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one
IV- (5a,16b)-N-Acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one
V- (5a,16b)-N-Acetyl-16-(2-(acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one

Based on the current information available to the Office of Controlled Substances, it appears that the above substance is:

Controlled	☐
Not Controlled	X

under the schedules of the *Controlled Drugs and Substances Act* (CDSA) for the following reason(s):

- The substances have not been reported to display any anabolic activity nor derived from an anabolic steroid.

Prepared by: _____ Date: _____
Vincent Marleau

Verified by: _____ Date: _____
Mark Kozlowski

Approved by: _____ Date: _____
DIRECTOR, OFFICE OF CONTROLLED SUBSTANCES

This status was requested by: "third party information removed as per agreement with applicant"

Drug Status Report

Drugs:
I- 17b-Hydroxy-5-androstano[3,2-c]pyrazole
II- 5a-N-Acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate
III- 5a-N-Acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one
IV- (5a,16b)-N-Acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one
V- (5a,16b)-N-Acetyl-16-(2-(acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one

Drug Name Status:
I- 17b-Hydroxy-5-androstano[3,2-c]pyrazole
II- 5a-N-Acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate
III- 5a-N-Acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one
IV- (5a,16b)-N-Acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one
V- (5a,16b)-N-Acetyl-16-(2-(acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one are the common names.

Chemical Name:
I- (3aS,3bR,5aS,10aS,10bS,12aS)-10a,12a-dimethyl-3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1(2H)-one
II- (3aS,3bR,5aS,10aS,10bS,12aS)-7-acetyl-10a,12a-dimethyl-3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1-yl acetate
III- (3aS,3bR,5aS,10aS,10bS,12aS)-7-acetyl-10a,12a-dimethyl-3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-tetradecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-1(2H)-one
IV- (2S,3aS,3bR,5aS,10aS,10bS,12aS)-7-acetyl-10a,12a-dimethyl-1-oxo-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-2-yl acetate
V- (2S,3aS,3bR,5aS,10aS,10bS,12aS)-7-acetyl-10a,12a-dimethyl-1-oxo-1,2,3,3a,3b,4,5,5a,6,7,10,10a,10b,11,12,12a-hexadecahydrocyclopenta[5,6]naphtho[1,2-f]indazol-2-yl 2-acetoxyacetate

Chemical structure:



I



II



III



IV



V

Molecular Formula: I- $C_{20}H_{28}N_2O$; II- $C_{24}H_{32}N_2O_3$; III- $C_{22}H_{30}N_2O_2$; IV- $C_{24}H_{32}N_2O_4$; V- $C_{26}H_{34}N_2O_6$.

CAS-RN: I- 129545-93-3; II- N/A; III- N/A; IV- N/A; V- N/A.

Pharmacological class / Application: Steroids

International status:

US: 17b-Hydroxy-5-androstano[3,2-c]pyrazole, 5a-N-acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate, 5a-N-acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one, (5a,16b)-N-acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one and (5a,16b)-N-acetyl-16-(2-(acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one are not listed specifically in the Schedules to the US *Controlled Substances Act* and are not mentioned anywhere on the DEA website.

United Nations: The substances are not listed on the Yellow List - List of Narcotic Drugs under International Control, the Green List - List of Psychotropic Substances under International Control, nor the Red List - List of Precursors and Chemicals Frequently Used in the Illicit Manufacture of Narcotic Drugs and Psychotropic Substances under International Control.

Canadian Status: 17b-Hydroxy-5-androstano[3,2-c]pyrazole, 5a-N-acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate, 5a-N-acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one, (5a,16b)-N-acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one and (5a,16b)-N-acetyl-16-(2-(acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one are not listed specifically in the CDSA. The substances are intermediates related to the synthesis of 16beta-hydroxy stanozolol, a metabolite of stanozolol, which is currently listed as sub-item 23(38) of Schedule IV to the CDSA under the heading “Anabolic steroids and their derivatives including:”. However since none of these steroids are derivatives of stanozolol nor reported to display any anabolic activity, they cannot be included under item 23 of Schedule IV to the CDSA.

Recommendation: 17b-Hydroxy-5-androstano[3,2-c]pyrazole, 5a-N-acetyl-2'H-androst-16-en-2-eno[3,2-c]pyrazol-17-ol Acetate, 5a-N-acetyl-2'H-androst-2-eno[3,2-c]pyrazol-17-one, (5a,16b)-N-acetyl-16-acetyloxy-2'H-androst-2-eno[3,2-c]pyrazol-17-one and (5a,16b)-N-acetyl-16-(2-(acetyloxy)acetyloxy)-2'H-androst-2-eno[3,2-c]pyrazol-17-one are not included in item 23 of Schedule IV to the CDSA and are not controlled substances.

Date: August 13th, 2012.